I think an important nuance of this argument is that Joe has confirmed to RJS and to me that we do not need US FDA approval of the vaccine, only the IND, in order to move forward with the overseas/BK approvals.

So even if the US trials would still be under debate (which we are also being told is not at issue... but that can be followed up on the call), the work can continue on overseas approvals, and US trials would not be an obstacle to that approval path.